Zobrazeno 1 - 10
of 6 935
pro vyhledávání: ''
Autor:
Otis W. Brawley, Jeromie Ballreich, Lin Wang, Hwanhee Hong, Channing J. Paller, G. Caleb Alexander
Publikováno v:
Value Health
Objectives To assess the cost-effectiveness of systemic treatments for metastatic castration-sensitive prostate cancer from the US healthcare sector perspective with a lifetime horizon. Methods We built a partitioned survival model based on a network
Publikováno v:
Value Health
Adjuvant chemotherapy is not recommended for patients with average-risk stage II (T3N0) colon cancer. Nevertheless, a subgroup of these patients who are CDX2-negative might benefit from adjuvant chemotherapy. We evaluated the cost-effectiveness of te
Publikováno v:
Value in Health. 24:1746-1753
Objectives Real option value (ROV) is created when a drug enables a patient to live long enough to benefit from a future innovation. Few studies have quantified ROV in the real world. We aimed to estimate the ex post ROV for ipilimumab in metastatic
Autor:
James W. Shaw, Bryan Bennett, Katie Noon, Kim Cocks, Christopher Kiff, Andrew Trigg, Madeleine King, Michael DeRosa, Dionysios Ntais, Fiona Taylor
Publikováno v:
Value in Health. 24:1651-1659
Objectives There is growing interest in condition-specific preference measures, including the European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions (QLU-C10D). This research assessed the implica
Publikováno v:
Value in Health. 24:1520-1530
Objectives Although there is a growing body of evidence suggesting that cannabinoids may relieve symptoms of some illnesses, they are relatively high-cost therapies compared with illicit growth and supply. This article aimed to comprehensively review
Publikováno v:
Value in Health. 24:1279-1284
Objectives Health systems (nonfederal hospitals and clinics) are the second major source for drug expenditure in the United States. Opioids prescribed in these healthcare settings are commonly short-acting opioids that can lead to persistent opioid u
Autor:
Tim Kampmeier, Abdul Jabbar Omar Alsaleh, Jenny Pham, Stefan Schraag, Martin Westphal, S. Rehberg
Publikováno v:
Value in Health. 24:939-947
Objectives It is not known whether using propofol total intravenous anaesthesia (TIVA) to reduce incidence of postoperative nausea and vomiting (PONV) is cost-effective. We assessed the economic impact of propofol TIVA versus inhalational anesthesia
Autor:
Michael N Dalili, José A López-López, Deborah M Caldwell, Kyla H Thomas, Mark Stevenson, David Phillippo, Edna Keeney, Nicky J Welton, Marcus R. Munafò
Publikováno v:
Keeney, E, Welton, N J, Stevenson, M, Dalili, M N, López-López, J A, Caldwell, D M, Phillippo, D M, Munafò, M R & Thomas, K H 2021, ' Cost-Effectiveness Analysis of Smoking Cessation Interventions in the United Kingdom Accounting for Major Neuropsychiatric Adverse Events ', Value in Health, vol. 24, no. 6, pp. 780-788 . https://doi.org/10.1016/j.jval.2020.12.012
Value in Health
Value in Health
OBJECTIVES: Smoking is a leading cause of death worldwide. Cessation aids include varenicline, bupropion, nicotine replacement therapy (NRT), and e-cigarettes at various doses (low, standard and high) and used alone or in combination with each other.
Publikováno v:
Value Health
Objectives To estimate the effect of filgrastim-sndz market entry on patient out-of-pocket costs and claim payments for filgrastim products. Methods This study used a single interrupted time series design with longitudinal, nationally representative,
Publikováno v:
Value in Health. 23:1543-1551
Objectives Reexamine cost-effectiveness of riluzole in the treatment of amyotrophic lateral sclerosis (ALS) in light of recent advances in disease staging and understanding of stage-specific drug effect. Methods ALS was staged according to the “fin